Urotensin II and Vascular Tone in Cirrhosis
NCT00163995 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2007-07-26
Summary
This study looks at the iontophoresis of urotensin II in chronic liver disease patients.
Conditions
- Liver Diseases
- Cirrhosis
Interventions
- DRUG
-
urotensin II
Sponsors & Collaborators
-
Bayside Health
lead OTHER_GOV
Principal Investigators
-
William W Kemp, MBBS, FRACP · The Alfred
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
Countries
- Australia
Study Locations
More Related Trials
-
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
NCT06539507 ·Status: RECRUITING ·Phase: PHASE1
-
A Study Designed to Evaluate the Pharmacokinetic Profile of Abiraterone
NCT04295161 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
NCT06488313 ·Status: RECRUITING ·Phase: PHASE2
-
Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects
NCT04416126 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment
NCT00828932 ·Status: COMPLETED ·Phase: PHASE1
-
Gut Transit Effect on Enterohepatic Circulation
NCT03501498 ·Status: COMPLETED ·Phase: NA
-
A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function
NCT01516047 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects
NCT00854659 ·Status: COMPLETED ·Phase: PHASE1
-
Correlative Cohort Study on the Clinical Features and Prognosis of Drug-induced Liver Injury
NCT04302506 ·Status: UNKNOWN
-
Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function
NCT02442258 ·Status: COMPLETED ·Phase: PHASE1
-
Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers
NCT01784536 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated Hepatitis
NCT06750588 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Pilot Study of AVT16 in Healthy Adult Subjects
NCT06400719 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
NCT03289234 ·Status: COMPLETED ·Phase: PHASE1
-
Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue
NCT01319916 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers
NCT00099450 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
NCT06928779 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects
NCT02207595 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy Volunteers
NCT00912431 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics
NCT04252495 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment
NCT05376839 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Compare the Safety, Tolerability, and Pharmacokinetics of CTP-692 Versus D-serine in Healthy Volunteers
NCT03778320 ·Status: COMPLETED ·Phase: PHASE1
-
Hepatic Impairment Trial of Obeticholic Acid
NCT01904539 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection
NCT01118663 ·Status: TERMINATED ·Phase: PHASE3
-
Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants
NCT04990310 ·Status: COMPLETED ·Phase: PHASE1